Exploration of the Correlations Between Interferon-γ in Patient Serum and HEPACAM in Bladder Transitional Cell Carcinoma, and the Interferon-γ Mechanism Inhibiting BIU-87 Proliferation

Authors:

Abstract
Interferon-γ inhibits cancer cell proliferation and induces re-expression of different tumor suppressor genes. As a candidate, HEPACAM is almost lost in bladder transitional cell carcinoma. To our knowledge whether interferon-γ inhibits BIU-87 proliferation and re-expresses HEPACAM mRNA is still unknown. Thus, we probed the mechanism and examined the correlations between interferon-γ in patient serum and HEPACAM in bladder transitional cell carcinoma. Using enzyme-linked immunosorbent assay we measured serum interferon-γ in 27 men and 6 women, and 15 volunteers. Disease was Ta–T1 in 12 patients, T2–T4 in 21, low grade in 25, high grade in 8, primary in 13 and recurrent in 20. A total of 33 cancer and 26 adjacent tissues were examined by immunohistochemistry to detect HEPACAM protein and ensure the position. Under interferon-γ stimulation we detected BIU-87 proliferation by MTT assay. Cell cycles were examined by flow cytometry. HEPACAM mRNA expression was determined by reverse transcription-polymerase chain reaction. Western blot was used to detect p21WAF1. Interferon-γ was remarkably low in patients with bladder transitional cell carcinoma vs volunteers (p HEPACAM mRNA (p 0/G1 and p21WAF1 was concurrently increased in response to interferon-γ (p WAF1 up-regulation to arrest cells at the G0/G1 phase.

This publication has 18 references indexed in Scilit: